ライフサイエンスコーパス: adenosine monophosphate

1 n other cells by releasing a compound called adenosine monophosphate.

2 toxin fails to increase intracellular cyclic adenosine monophosphate.

3 osine, an adenosine surrogate, and of cyclic adenosine monophosphate.

4 xchange protein directly activated by cyclic adenosine monophosphate 1 (EPAC1)-RAP1-dependent model o

5 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cGAMP) is the endogenous l

6 nd messenger, cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cGAMP)(4-7).

7 e nucleotide signaling molecule 3',5'-cyclic adenosine monophosphate (3',5'-cAMP) plays important phy

8 e stimulation of A2a receptors causes cyclic adenosine monophosphate accumulation at the back of cell

9 -chlorophenyl hydrazone (CCCP) treatment and adenosine monophosphate activated protein kinase (AMPK)

10 s of adiponectin receptor-2, inactivation of adenosine monophosphate activated protein kinase (AMPK),

11 th DENV activates the metabolic regulator 5' adenosine-monophosphate activated kinase (AMPK), and tha

12 Exercise activates adenosine monophosphate-activated kinase (AMPK) and miti

13 UDCA activates SMILE gene expression through adenosine monophosphate-activated kinase phosphorylation

14 d kinase) enzyme, which belongs to the AMPK (adenosine monophosphate-activated kinase) family, was es

15 promoter activity and gene expression in an adenosine monophosphate-activated kinase-dependent manne

16 Adenosine monophosphate-activated protein (AMP)-activate

17 The activity of the metabolic sensor adenosine monophosphate-activated protein kinase (AMPK)

18 Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK)

19 Adenosine monophosphate-activated protein kinase (AMPK)

20 Adenosine monophosphate-activated protein kinase (AMPK)

21 tion while activating "stress" signals of 5' adenosine monophosphate-activated protein kinase (AMPK)

22 in high-altitude populations is one for the adenosine monophosphate-activated protein kinase (AMPK)

23 Adenosine monophosphate-activated protein kinase (AMPK)

24 5'-Adenosine monophosphate-activated protein kinase (AMPK)

25 Adenosine monophosphate-activated protein kinase (AMPK)

26 The activation of adenosine monophosphate-activated protein kinase (AMPK)

27 that regulates metabolism and growth through adenosine monophosphate-activated protein kinase (AMPK)

28 hat this response does not require canonical adenosine monophosphate-activated protein kinase (AMPK)

29 at the antidiabetes drug metformin (MET), an adenosine monophosphate-activated protein kinase (AMPK)

30 Phosphorylation quantification of adenosine monophosphate-activated protein kinase (AMPK)

31 Adenosine monophosphate-activated protein kinase (AMPK)

32 Adenosine monophosphate-activated protein kinase (AMPK)

33 A targeted screen identified a role for 5' adenosine monophosphate-activated protein kinase (AMPK)

34 ses involved in autophagy induction such as; Adenosine monophosphate-activated protein kinase (AMPK)

35 5'adenosine monophosphate-activated protein kinase (AMPK)

36 fatty acid beta-oxidation, and activating 5'adenosine monophosphate-activated protein kinase (AMPK)

37 5'-Adenosine monophosphate-activated protein kinase (AMPK)

38 The increase in the ROS level activated 5' adenosine monophosphate-activated protein kinase (AMPK),

39 antagonized the catalytic alpha1 subunit of adenosine monophosphate-activated protein kinase (AMPK),

40 nvolved in energy stress response, including adenosine monophosphate-activated protein kinase (AMPK),

41 f rapamycin (mTORC1) to the energy sensor 5'-adenosine monophosphate-activated protein kinase (AMPK),

42 mechanistic target of rapamycin (mTOR), and adenosine monophosphate-activated protein kinase (AMPK)-

43 et of the peptide via modulation of upstream adenosine monophosphate-activated protein kinase (AMPK)-

44 competent up to p-Akt activation; however, p-adenosine monophosphate-activated protein kinase (p-AMPK

45 f heme oxygenase-1 (HO-1) and phosphorylated adenosine monophosphate-activated protein kinase (pAMPK)

46 LPI induced adenosine monophosphate-activated protein kinase activat

47 Ex vivo experiments demonstrated that adenosine monophosphate-activated protein kinase activat

48 e induction of trained immunity, whereas the adenosine monophosphate-activated protein kinase activat

49 enosine triphosphate-citrate lyase inhibitor/adenosine monophosphate-activated protein kinase activat

50 kinases 1/2, phosphatase and tensin homolog, adenosine monophosphate-activated protein kinase alpha,

51 of the metabolic modulators p38-alpha and 5' adenosine monophosphate-activated protein kinase alpha.

52 hich controls IEB permeability by inhibiting adenosine monophosphate-activated protein kinase and inc

53 regulates IEB permeability by inhibiting an adenosine monophosphate-activated protein kinase and inc

54 (PTEN) induces activation of the phospho-5' adenosine monophosphate-activated protein kinase and pho

55 adou et al. report that the metabolic sensor adenosine monophosphate-activated protein kinase influen

56 hate-activated protein kinase, total protein adenosine monophosphate-activated protein kinase levels,

57 However, it activates adenosine monophosphate-activated protein kinase only in

58 d association with nitric oxide synthase and adenosine monophosphate-activated protein kinase pathway

59 use adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase play ce

60 Cardiac mitochondrial dysfunction and adenosine monophosphate-activated protein kinase seem as

61 creased hepatocyte apoptosis, independent of adenosine monophosphate-activated protein kinase signali

62 rectly targets the 3' untranslated region of adenosine monophosphate-activated protein kinase subunit

63 However, the level of total adenosine monophosphate-activated protein kinase was sev

64 -dependent phosphorylation of distinct AMPK (adenosine monophosphate-activated protein kinase) family

65 cAMP-response element binding, p38 MAPK and adenosine monophosphate-activated protein kinase) in way

66 f ATM (ataxia telangiectasia mutated)/PRKAA (adenosine monophosphate-activated protein kinase) signal

67 which represses mTOR signaling by activating adenosine monophosphate-activated protein kinase, has be

68 response, leading to decreased activation of adenosine monophosphate-activated protein kinase, total

69 ng from the master energy-regulating kinase, adenosine monophosphate-activated protein kinase, while

70 Genes near adenosine monophosphate-activated protein kinase-alpha1

71 lmodulin-dependent kinase kinase-beta and 5' adenosine monophosphate-activated protein kinase-depende

72 hosphate-citrate lyase and the activation of adenosine monophosphate-activated protein kinase.

73 Here we found that the energy-sensing adenosine-monophosphate-activated protein kinase (AMPK)

74 onse is cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) (cGAMP) synthase (cGAS), w

75 adenosine triphosphate (ATP) hydrolysis into adenosine monophosphate (AMP) and 2) AMP into adenosine

76 We investigated 5'-adenosine monophosphate (AMP) and 5'-uridine monophospha

77 The modulatory effect of adenosine monophosphate (AMP) and adenosine diphosphate

78 w that while Gh can form hydrogen bonds with adenosine monophosphate (AMP) during incorporation, this

79 ediates AMPylation, a covalent attachment of adenosine monophosphate (AMP) from ATP to hydroxyl side

80 Generation of adenosine monophosphate (AMP) in blood is driven by cell

81 transcription factor 2 (ATF2) to the cyclic adenosine monophosphate (AMP) response element (CRE) in

82 In eukaryotes, cellular levels of adenosine monophosphate (AMP) signal the metabolic state

83 lasmic sensor cyclic guanosine monophosphate-adenosine monophosphate (AMP) synthase (cGAS) drives IRF

84 Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS) recognizes

85 l modification that involves the addition of adenosine monophosphate (AMP) to a protein.

86 dence strongly indicated that it can convert adenosine monophosphate (AMP) to adenosine.

87 ein, HYPE/FicD, catalyzes the addition of an adenosine monophosphate (AMP) to the ER chaperone, BiP,

88 Adenosine monophosphate (AMP) was used as a model compou

89 idly hydrolyzed by the ecto-ATPase CD39 into adenosine monophosphate (AMP), and it is AMP that regula

90 ve catabolites: adenosine diphosphate (ADP), adenosine monophosphate (AMP), inosine monophosphate (IM

91 precursors, adenosine diphosphate (ADP) and adenosine monophosphate (AMP), using mouse heart, kidney

92 ow expression of SIRT1 and PGC1alpha and low adenosine monophosphate (AMP)-activated kinase (AMPK) ac

93 We found that the energy-sensing adenosine monophosphate (AMP)-activated protein kinase (

94 The adenosine monophosphate (AMP)-activated protein kinase (

95 longed metformin treatment on phosphorylated adenosine monophosphate (AMP)-activated protein kinase (

96 The activity of the energy sensor adenosine monophosphate (AMP)-activated protein kinase (

97 As adenosine monophosphate (AMP)-activated protein kinase b

98 Acute pharmacological activation of adenosine monophosphate (AMP)-kinase using 5-aminoimidaz

99 tivated by glucose 6-phosphate (Glc-6-P) and adenosine monophosphate (AMP).

100 se-, and triose-phosphates, UDP-glucose, and adenosine monophosphate (AMP).

101 hate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP); and antioxidants, the sum

102 reduction in plasma adenosine (P = 0.03) and adenosine monophosphate (AMP; P < 0.0001) concentrations

103 iphosphate [ATP]/adenosine diphosphate [ADP]/adenosine monophosphate [AMP], nicotinamide adenine dinu

104 Glucagon and a cyclic adenosine monophosphate analog increased promoter activi

105 te its transcription in response to a cyclic adenosine monophosphate analog.

106 nopus oocytes in the presence of both cyclic adenosine monophosphate and Ca(2+) results in Ca(2+) inf

107 enzyme involved in the regulation of cyclic adenosine monophosphate and cyclic guanosine monophospha

108 culture and decidualized with 8-bromo-cyclic adenosine monophosphate and medroxyprogesterone acetate.

109 Nucleotide (ATP, adenosine diphosphate, adenosine monophosphate) and nucleoside (adenosine and i

110 Structures of adenosine monophosphate- and DNA- bound M2-1 establish t

111 In 3,5-cyclic adenosine monophosphate assays, the novel series behaved

112 ly, we demonstrate that Akt up-regulates the adenosine monophosphate-associated kinase (AMPK)-related

113 Strikingly, the measured on-rate for cyclic adenosine monophosphate binding is two orders of magnitu

114 educed renal ATP, adenosine diphosphate, and adenosine monophosphate, but not adenosine levels, durin

115 Cyclic di-adenosine monophosphate (c-di-AMP) is a broadly conserve

116 Cyclic di-3',5'-adenosine monophosphate (c-di-AMP) is a broadly conserve

117 Cyclic di-adenosine monophosphate (c-di-AMP) is a widely distribut

118 Cyclic di-adenosine monophosphate (c-di-AMP) is an important secon

119 The nucleotide cyclic di-3',5'- adenosine monophosphate (c-di-AMP) was recently identifi

120 Detection of cyclic-di-adenosine monophosphate (c-di-AMP), a bacterial second m

121 the STING agonist bis-(3'-5')-cyclic dimeric adenosine monophosphate (c-di-AMP).

122 n ADCY5 was studied by measurement of cyclic adenosine monophosphate (cAMP) accumulation under stimul

123 l had an impaired capacity to degrade cyclic adenosine monophosphate (cAMP) and a blunted pharmacolog

124 mediated initially by an increase in cyclic adenosine monophosphate (cAMP) and a subsequent inactiva

125 Diminished cyclic adenosine monophosphate (cAMP) and augmented cyclic guan

126 The cyclic adenosine monophosphate (cAMP) and Ca(2+) signaling path

127 Cyclic adenosine monophosphate (cAMP) and cyclic guanosine mono

128 lation of the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine mono

129 PDE11A4, which degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine mono

130 The spatiotemporal regulation of cyclic adenosine monophosphate (cAMP) and its dynamic interacti

131 Cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA

132 s contributed to an increase in basal cyclic adenosine monophosphate (cAMP) and vasodilator-stimulate

133 In 3,5-cyclic adenosine monophosphate (cAMP) assays, the novel series

134 In 3,5-cyclic adenosine monophosphate (cAMP) assays, the novel series

135 prostaglandin E1-induced increase in cyclic adenosine monophosphate (cAMP) by ADP was impaired, wher

136 udies exploring the importance of the cyclic adenosine monophosphate (cAMP) cascade in major depressi

137 bunit through formation of a PDE-PKAR-cyclic adenosine monophosphate (cAMP) complex (the termination

138 cally, coronin 1-deficiency increased cyclic adenosine monophosphate (cAMP) concentrations to suppres

139 Neuropeptides that exert cyclic adenosine monophosphate (cAMP) dependent effects play an

140 Cyclic adenosine monophosphate (cAMP) drives genetic polycystic

141 mooth muscle cells (hCASMCs) to 3',5'-cyclic adenosine monophosphate (cAMP) generation and phosphoryl

142 phodiesterase (PDE4) and elevation of cyclic adenosine monophosphate (cAMP) has emerged as a promisin

143 s associated with increased levels of cyclic adenosine monophosphate (cAMP) in cholangiocytes lining

144 hnology have revealed oscillations of cyclic adenosine monophosphate (cAMP) in insulin-secreting cell

145 centration of the secondary messenger cyclic adenosine monophosphate (cAMP) in MLT cells, in response

146 rom the canalicular membrane, whereas cyclic adenosine monophosphate (cAMP) increases plasma membrane

147 Cyclic 3',5'-adenosine monophosphate (cAMP) is a critical and ubiquit

148 3',5'-Cyclic adenosine monophosphate (cAMP) is a pivotal second messe

149 Cyclic adenosine monophosphate (cAMP) is a second messenger wit

150 Cyclic-3',5'-adenosine monophosphate (cAMP) is an ancient second mess

151 Cyclic adenosine monophosphate (cAMP) is an important mediator

152 Cyclic adenosine monophosphate (cAMP) is very important in the

153 a PDE that regulates cardiac myocyte cyclic adenosine monophosphate (cAMP) levels and myocardial con

154 hibitory protein Galpha(o1) to reduce cyclic adenosine monophosphate (cAMP) levels in mice and in GPR

155 and kidney (PKD) diseases, increased cyclic adenosine monophosphate (cAMP) levels trigger hepatorena

156 Intracellular cyclic adenosine monophosphate (cAMP) levels tune the voltage r

157 ds such as elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, and depends on up

158 E17G increased cyclic adenosine monophosphate (cAMP) levels, and this increase

159 olin, both of which increase platelet cyclic adenosine monophosphate (cAMP) levels.

160 ts that raise intracellular Ca(2+) or cyclic adenosine monophosphate (cAMP) levels.

161 he GNAS gene, which encodes the 3',5'-cyclic adenosine monophosphate (cAMP) pathway-associated G-prot

162 alone can swiftly increase the 3',5'-cyclic adenosine monophosphate (cAMP) production.

163 Cyclic adenosine monophosphate (cAMP) regulates long-term poten

164 o have taken effect through increased cyclic adenosine monophosphate (cAMP) response element binding

165 OPN3 negatively regulates the cyclic adenosine monophosphate (cAMP) response evoked by MC1R v

166 ond, we found that phosphorylation of cyclic adenosine monophosphate (cAMP) responsive-element-bindin

167 A (PKA) is the major receptor for the cyclic adenosine monophosphate (cAMP) secondary messenger in eu

168 FTO augmented second messenger 3', 5'-cyclic adenosine monophosphate (cAMP) signaling and suppressed

169 demonstrate a differential effect of cyclic adenosine monophosphate (cAMP) signaling between normal

170 DISC1 also regulates cyclic adenosine monophosphate (cAMP) signaling by increasing t

171 Using a marker of the cyclic adenosine monophosphate (cAMP) signaling cascade and lip

172 ell disease and activated through the cyclic adenosine monophosphate (cAMP) signaling pathway.

173 duct ligation (BDL) by activation of cyclic adenosine monophosphate (cAMP) signaling.

174 ncodes a membrane protein involved in cyclic adenosine monophosphate (cAMP) signaling.

175 iesterase 4D (PDE4D), which regulates cyclic adenosine monophosphate (cAMP) signaling.

176 ent increased intracellular levels of cyclic adenosine monophosphate (cAMP) that turned on protein ki

177 Binding of 3',5'-cyclic adenosine monophosphate (cAMP) to hyperpolarization-acti

178 or D1 (DRD1) via the second messenger cyclic adenosine monophosphate (cAMP) to synthetic promoters co

179 were treated with Angiopoietin 1 and cyclic adenosine monophosphate (cAMP) to vary the Pd of the HUV

180 In this study, we showed that cyclic adenosine monophosphate (cAMP) treatment induced DON pro

181 Levels of cyclic adenosine monophosphate (cAMP) were elevated over sustai

182 f phenylalanine, acetylhistidine, and cyclic adenosine monophosphate (cAMP) were found in urine sampl

183 Here we demonstrate that cyclic adenosine monophosphate (cAMP), a second messenger downs

184 Here we examine whether increases in cyclic adenosine monophosphate (cAMP), an intracellular signali

185 th a small molecule second messenger, cyclic adenosine monophosphate (cAMP), and a downstream cell-se

186 y modulated by a HCN channel blocker, cyclic adenosine monophosphate (cAMP), and neuromodulators.

187 rchestrated by waves of extracellular cyclic adenosine monophosphate (cAMP), and previous theory sugg

188 In beta cells, Ca(2+), cyclic adenosine monophosphate (cAMP), and Protein Kinase A (PK

189 s have implicated defective dopamine, cyclic adenosine monophosphate (cAMP), and Ras homeostasis.

190 MRE-269 increased intracellular 3',5'-cyclic adenosine monophosphate (cAMP), augmented glucose-stimul

191 The cyclic adenosine monophosphate (cAMP), mitogen-activated protei

192 Cyclic adenosine monophosphate (cAMP), when added, induces cyst

193 R reduced ability of SCT to stimulate cyclic adenosine monophosphate (cAMP), with signaling augmented

194 conductance regulator (CFTR) gene, a cyclic Adenosine MonoPhosphate (cAMP)-dependent chloride channe

195 helial barrier can be up-regulated by cyclic adenosine monophosphate (cAMP)-dependent mechanisms thro

196 e regulatory subunit (PRKAR1A) of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase

197 rmore, we demonstrated that Tregs use cyclic adenosine monophosphate (cAMP)-dependent protein kinase

198 spatiotemporal signaling control, the cyclic adenosine monophosphate (cAMP)-dependent protein kinase

199 roach was applied to the prototypical cyclic adenosine monophosphate (cAMP)-dependent protein kinase

200 coding the gamma-catalytic subunit of cyclic adenosine monophosphate (cAMP)-dependent protein kinase

201 Cyclic adenosine monophosphate (cAMP)-dependent signaling modul

202 Cyclic 3'5' adenosine monophosphate (cAMP)-dependent-protein kinase

203 motes beta cell Tcf7 expression via a cyclic adenosine monophosphate (cAMP)-independent and extracell

204 (CT)-induced diarrhea is mediated by cyclic adenosine monophosphate (cAMP)-mediated active Cl- secre

205 odendritic domain, depends on ongoing cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) le

206 lation of the prostaglandin E2 (PGE2)-cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) si

207 on gradient of the signaling molecule cyclic adenosine monophosphate (cAMP).

208 converging on a ubiquitous messenger, cyclic adenosine monophosphate (cAMP).

209 d including increased levels of 3'-5'-cyclic adenosine monophosphate (cAMP).

210 ing region (BBR) of EPAC1, similar to cyclic adenosine monophosphate (cAMP).

211 lyl cyclase to increase intracellular cyclic adenosine monophosphate (cAMP).

212 chemotaxis towards emitted pulses of cyclic adenosine monophosphate (cAMP).

213 Downstream of calcium, the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pa

214 P-ribose) polymerase 1 (PARP1) by the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) sy

215 ntified as full antagonist ligands on cyclic adenosine monophosphate (cAMP, KB = 4.9 and 5.9 nM, resp

216 aling pathway function (Ras activity, cyclic adenosine monophosphate [cAMP], and dopamine levels).

217 lutamatergic, monoaminergic, calcium, cyclic adenosine monophosphate [cAMP], dopamine- and cAMP-regul

218 horylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [cAMP]-regulated phospho-protein

219 The cyclic AMP (adenosine monophosphate; cAMP)-hydrolyzing protein PDE4B

220 s as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic that induces the

221 ne stimulates cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) production in vitro more

222 tification of cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) as a cyt

223 he DNA sensor cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) binds to

224 sis activated cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) in macro

225 ion activates cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) to produ

226 ulating 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), an agonist of the inter

227 STING), 2'3'- cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), robustly augmented and

228 STING ligand cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), we stimulated periphera

229 r STING, 2'3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP).

230 production of cyclic guanosine monophosphate-adenosine monophosphate (cyclic GMP-AMP, or cGAMP), whic

231 rase 10A (PDE10A), a dual-specificity cyclic adenosine monophosphate/cyclic guanosine monophosphate-i

232 ve condition resulting from mutations in the adenosine monophosphate deaminase 2 gene (AMPD2).

233 c adenosine monophosphate levels; and cyclic adenosine monophosphate-dependent protein kinase A-media

234 ng the gamma-catalytic subunit of the cyclic adenosine monophosphate-dependent protein kinase, the mu

235 ivation of neuronal EP2 receptors and cyclic adenosine monophosphate-dependent protein kinase.

236 horylation of its headpiece domain by cyclic adenosine monophosphate-dependent protein kinase.

237 It is highly debated how cyclic adenosine monophosphate-dependent regulation (CDR) of th

238 Optogenetic upregulation of cyclic adenosine monophosphate during the day increases sleep i

239 degraded into a mono-organophosphate (e.g., adenosine monophosphate) during heating.

240 AVP/cyclic adenosine monophosphate enhance the phosphorylation of t

241 e protein directly activated by cyclic-3',5'-adenosine monophosphate (Epac) on Nav1.4 currents from i

242 nists further confirmed by functional cyclic adenosine monophosphate experiments.

243 nylyl cyclase (AC) and an increase in cyclic adenosine monophosphate formation.

244 easing the pathway flux, and influencing the adenosine monophosphate/guanosine monophosphate ratio.

245 Normal: p < 0.001; HF: p < 0.01), and cyclic adenosine monophosphate (HF: p < 0.001).

246 We show that cyclic-di-adenosine monophosphate in live Gram-positive bacteria i

247 ores the suppressive effects of 3',5'-cyclic adenosine monophosphate in lymphocytes.

248 beta) is highly associated with cAMP (cyclic adenosine monophosphate)-independent dopamine D(2) recep

249 Cyclic adenosine monophosphate-induced enteroid intracellular p

250 )-TOC demonstrated higher potency for cyclic adenosine monophosphate inhibition (half maximal effecti

251 using a knockin mouse line expressing cyclic adenosine monophosphate-insensitive HCN4 channels.

252 is a key molecule, since via degradation of adenosine monophosphate into adenosine, endorses the gen

253 (GP)IIb/IIIa activation and decreased cyclic adenosine monophosphate levels (n = 6, P < .01) in plate

254 n of the cardiac stress marker NR4A1; cyclic adenosine monophosphate levels; and cyclic adenosine mon

255 STING agonist cyclic guanosine monophosphate-adenosine monophosphate (NP-cGAMP) in mouse models of lu

256 that regulates the phosphodiesterase/cyclic adenosine monophosphate pathway and modulates T cell res

257 ability of RvD5n-3 DPA to upregulate cyclic adenosine monophosphate, phagocytosis of bacteria, and e

258 n-activated protein kinase) and cAMP (cyclic adenosine monophosphate)-PKA (protein kinase A) cascades

259 (UPR), intracellular ion homeostasis, cyclic adenosine monophosphate production and regulation of ins

260 nosine uptake by red blood cells, and cyclic adenosine monophosphate production by cells overexpressi

261 teoclast differentiation by enhancing cyclic adenosine monophosphate production through an unidentifi

262 her than canonical Galpha(s)-mediated cyclic adenosine-monophosphate production, explained 88% of the

263 giocytes show increased production of cyclic adenosine monophosphate, protein kinase A-dependent acti

264 m of ICAM-4 activation occurs via the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA)-depe

265 therapy, which elevates intracellular cyclic adenosine monophosphate/protein kinase A (cAMP-PKA) sign

266 acyclin which stimulates the platelet cyclic adenosine monophosphate/protein kinase A (cAMP/PKA)-sign

267 Previous studies have implicated the cyclic adenosine monophosphate/protein kinase A pathway as well

268 nitines, including inosine monophosphate and adenosine monophosphate (purine metabolism), malic acid

269 ed the role of DARPP-32 (dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 320

270 trophic factor and phosphorylation of cyclic adenosine monophosphate response element binding and neu

271 expression of the binding protein of cyclic adenosine monophosphate response element binding protein

272 own that nuclear transcription factor cyclic adenosine monophosphate response element binding protein

273 ated the functional regulation of the cyclic adenosine monophosphate response element binding protein

274 ional activity and phosphorylation of cyclic adenosine monophosphate response element binding protein

275 tion and is required for signaling to cyclic adenosine monophosphate response element-binding protein

276 r regions of the transcription factor cyclic adenosine monophosphate response element-binding protein

277 logous protein, and activation of the cyclic adenosine monophosphate response element-binding protein

278 ISC1 caused a significant increase of cyclic adenosine monophosphate response element-binding protein

279 o evaluation of H(3)R agonism using a cyclic adenosine monophosphate response element-luciferase repo

280 promoter region as well as increased cyclic adenosine monophosphate response element-mediated transc

281 The transcription factor, cyclic adenosine monophosphate-responsive element modulator alp

282 ranscription coupling caused by CREB (cyclic adenosine monophosphate-responsive element-binding prote

283 phosphate, deoxyadenosine monophosphate, and adenosine monophosphate), results in ring opening to lin

284 he current study examined whether D1R-cyclic adenosine monophosphate signaling reduces neuronal firin

285 amine D1 receptor (D1R) activation of cyclic adenosine monophosphate signaling, which reduces PFC neu

286 cts of dopamine receptor D2 (DRD2) on cyclic adenosine monophosphate signaling; PDAC tissues had a sl

287 to ion channel Kir7.1, while lacking cyclic adenosine monophosphate stimulation, highlights a hetero

288 ed generation of the second messenger cyclic adenosine monophosphate, suggesting that alterations in

289 e (3polyP), adenosine triphosphate (ATP) and adenosine monophosphate supported equivalent growth rate

290 on of nuclear cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) and enhanced int

291 Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) detects intracel

292 The cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) senses invasion

293 he DNA sensor cyclic guanosine monophosphate-adenosine monophosphate synthase and the downstream adap

294 king STING or cyclic guanosine monophosphate-adenosine monophosphate synthase exhibit unaltered abili

295 he DNA sensor cyclic guanosine monophosphate-adenosine monophosphate synthase in micronuclei, leading

296 n of alkaline phosphatase, which can convert adenosine monophosphate to adenosine.

297 well-studied system is the binding of cyclic adenosine monophosphate to the cyclic nucleotide binding

298 exchange factor directly activated by cyclic adenosine monophosphate, which maintains vascular integr

299 Increases in cyclic adenosine monophosphate with forskolin caused enteroid i

300 osine 3',5'-cyclic monophosphate, and cyclic adenosine monophosphate with reduced spreading on collag